S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Forecast, Price & News

$7.28
-0.18 (-2.41%)
(As of 09/22/2023 ET)
Compare
Today's Range
$6.95
$7.50
50-Day Range
$6.66
$10.64
52-Week Range
$6.45
$28.20
Volume
287,574 shs
Average Volume
228,525 shs
Market Capitalization
$424.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.60

IGM Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
224.2% Upside
$23.60 Price Target
Short Interest
Bearish
28.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.21mentions of IGM Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$931,850 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.16) to ($4.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

159th out of 963 stocks

Pharmaceutical Preparations Industry

57th out of 458 stocks


IGMS stock logo

About IGM Biosciences (NASDAQ:IGMS) Stock

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Price History

IGMS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Why IGM Biosciences (IGMS) Stock Is Trading Higher
See More Headlines
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGMS Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
289
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$23.60
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+224.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-221,100,000.00
Net Margins
-14,007.47%
Pretax Margin
-13,995.76%

Debt

Sales & Book Value

Annual Sales
$1.07 million
Book Value
$6.67 per share

Miscellaneous

Free Float
25,150,000
Market Cap
$424.93 million
Optionable
Not Optionable
Beta
-0.24

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 70)
    CEO, Pres & Director
    Comp: $977.66k
  • Dr. Bruce A. Keyt (Age 70)
    Chief Scientific Officer
    Comp: $692.95k
  • Dr. Chris H. Takimoto FACP (Age 64)
    M.D., Ph.D., Chief Medical Officer
    Comp: $684.95k
  • Mr. Misbah Tahir (Age 48)
    Chief Financial Officer
  • Mr. TS Harigopal
    Sr. VP of Group Operations
  • Mr. Steven Weber (Age 47)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Paul C. Graffagnino
    VP of Legal Affairs
  • Ms. Suzette Tauber (Age 59)
    Chief HR Officer
  • Dr. Angus M. Sinclair Ph.D.
    Sr. VP of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Bus. Officer













IGMS Stock - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price forecast for 2023?

8 brokerages have issued 1-year price objectives for IGM Biosciences' shares. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they anticipate the company's stock price to reach $23.60 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2023?

IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS stock has decreased by 57.2% and is now trading at $7.28.
View the best growth stocks for 2023 here
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $0.03. The business earned $0.45 million during the quarter, compared to analysts' expectations of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. The company's revenue for the quarter was up 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Artal Group S.A. (5.85%), RA Capital Management L.P. (1.61%), BlackRock Inc. (1.99%), Goldman Sachs Group Inc. (1.15%), Great Point Partners LLC (0.86%) and State Street Corp (0.45%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Misbah Tahir.
View institutional ownership trends
.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $7.28.

How much money does IGM Biosciences make?

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $424.93 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis.

How many employees does IGM Biosciences have?

The company employs 289 workers across the globe.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.

This page (NASDAQ:IGMS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -